Data presented at ATS 2025 showed that lung improvement in paediatric cystic fibrosis (CF) patients receiving ETI therapy is ...

Skye has entered a partnership with Arecor aimed at developing a higher formulation of the former’s obesity candidate, ...

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

Novotech is a winner in the Diversity, Research and Development, and Marketing categories in the 2025 Pharmaceutical ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

The agreement will see international initiatives to fight the next pandemic, but funding remains the weak link.

The Japanese MHLW has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations for MM.

An ATS 2025 session presented data showing that anti–IL-5 biologics significantly cut exacerbations in coexisting asthma and ...

The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio for SSGJ-707.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...